Peptides for reducing or inhibiting bone resorption

Details Peptides for reducing or inhibiting bone resorption Peptides for reducing or inhibiting bone resorption

1994-09-08

1998-06-23

Russel, Jeffrey E.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 12, 514 13, 514 14, 514 15, 514 16, 514 17, 530324, 530325, 530326, 530327, 530328, 530329, A61K 3808, A61K 3810, C07K 706, C07K 708

Patent

active

057705658

ABSTRACT:
The present invention provides Arg-Gly-Asp peptides that can reduce or inhibit the binding of osteoclasts to a matrix such as bone or can selectively alter integrin receptor binding. The invention also provides methods of using the Arg-Gly-Asp peptides to reduce or inhibit osteoclast binding to a matrix, to reduce or inhibit bone resorption in a subject and to alter .alpha..sub.V .beta..sub.3 binding.

REFERENCES:
patent: 4517686 (1985-05-01), Ruoslahti et al.
patent: 4578079 (1986-03-01), Ruoslahti et al.
patent: 4589881 (1986-05-01), Pierschbacher et al.
patent: 4614517 (1986-09-01), Ruoslahti et al.
patent: 4661111 (1987-04-01), Ruoslahti et al.
patent: 4792525 (1988-12-01), Ruoslahti et al.
patent: 5041380 (1991-08-01), Ruoslahti et al.
patent: 5192746 (1993-03-01), Lobl et al.
patent: 5227469 (1993-07-01), Lazarus et al.
Athanasou, N.A. et al., "Species Differences in the Immunophenotype of Osteoclasts and Mononuclear Phagocytes." Calcif. Tissue. Int. 50:427-432 (1992).
Reinholt, Finn P. et al., "Osteopontin -a Possible Anchor of Osteoclasts to Bone." Proc. Natl. Acad. Sci. USA. 87/4473-4475 (1990).
Van Dijk, Simon et al., "Evidence That a Non-RGD Domain in Rat Osteopontin is Involved in Cell Attachment." J. Bone and Mineral Res. 8:1499-1506 (1993).
Chenu, C. et al., "Cloning and Sequence Analysis of Bovine Bone Sialoprotein cDNA: Conservation of Acidic Domains, Tyrosine Sulfation Consensus Repeats, and RGD Cell Attachment Domain." J. Bone and Mineral Res. 9:417-421 (1994).
Denhardt, David T. and Guo, Xiaojia, "Osteopontin: A Protein with Diverse Functions." FASEB J. 7:1475-1482 (1993).
Nesbitt, Stephen et al., "Biochemical Characterization of Human Osteoclast Integrins." J. Biol. Chem. 268:16737-16745 (1993).
Hughes, D.E. et al., "Integrin Expression in Human Bone." J. Bone & Mineral Res. 8:527-533 (1993).
Lakkakorpi, P.T. et al., "Vitronectin Receptor Has a Role in Bone Resorption but Does Not Mediate Tight Sealing Zone Attachment of Osteoclasts to the Bone Surface." J. Cell Biol. 115:1179-1186 (1991).
Ross, F. Patrick et al., "Interactions Between the Bone Matrix Proteins Osteopontin and Bone Sialoprotein and the Osteoclast Integrin .alpha..sub.v .beta. Potentiate Bone Resorption." J. Biol. Chem. 268:9901-9907 (1993).
Chuntharapal, Anan et al., "Blocking Monoclonal Antibodies to .alpha.V.beta.3 Integrin: A Unique Epitope of .alpha.V.beta.3 Integrin is Present on Human Osteoclasts." Experimental Cell Res. 205:345-352 (1993).
Helfrich, Miep H. et al., "Rat Osteoclasts Adhere to a Wide Range of cf RGD (Arg-Gly-Asp) Peptide-Containing Proteins, Including the Bone Sialoproteins and Fibronectin, via a .beta..sub.3 Integrin." J. Bone and Mineral Res. 7:335-343 (1992).
Miyauchi, Akimitsu et al., "Recognition of Osteopontin and Related Peptides by an .alpha..sub.v .beta..sub.3 Integrin Stimulates Immediate Cell Signals in Osteoclasts." J. Biol. Chem. 266:20369-20374 (1991).
Yamakawa, Kensuke et al., "An Arg-Gly-Asp Peptide Stimulates Ca.sup.2+ Efflux From Osteoclast Precursors Through a Novel Mechanism." American Physiological Society. 651-657 (1994).
Choi, Eric T. et al., "Inhibition of Neointimal Hyperplasia by Blocking .alpha..sub.v .beta..sub.3 Integrin with a Small Peptide Antagonist GpenGRGDSPCA." J. Vascular Surg. 19:125-134 (1994).
Flores, Myra E. et al., "RGD-Directed Attachment of Isolated Rat Osteoclasts to Osteopontin, Bone Sialoprotein, and Fibronectin." Experimental Cell Res. 201:526-530 (1992).
Mintz, Keith P. et al., "Purification and Fragmentation of Nondenatured Bone Sialoprotein: Evidence for a Cryptic, RGD-Resistant Cell Attachment Domain." J. Bone and Mineral Res. 8:985-995 (1993).
Horton, M.A. et al., "Arg-Gly-Asp (RGD) Peptides and the Anti-Vitronectin Receptor Antibody 23c6 Inhibit Dentine Resorption and Cell Spreading by Osteoclasts." Experimental Cell Res. 195:368-375 (1991).
Horton, Michael A. et al., "Modulation of Vitronectin Receptor-Mediated Osteoclast Adhesion by Arg-Gly-Asp Peptide Analogs: A Structure-Function Analysis." J. Bone and Mineral Res. 8:239-247 (1993).
Xie, Dong-lin and Homandberg, Gene A. "Fibronectin Fragments Bind to and Penetrate Cartilage Tissue Resulting in Proteinase Expression and Cartilage Damage." Biochimica et Biophysica Acta. 1182:189-196 (1993).
Fisher, John E. et al., "Inhibition of Osteoclastic Bone Resorption in Vivo by Echistatin, An Arginyl-glycyl-Aspartyl (RGD) -Containing Proteins." Endocrinology 132:1411-1413 (1993).
Sato, M. et al., "Echistatin is A Potent Inhibitor of Bone Resorption in Culture." J. Cell Biol. 111:1713-1723 (1990).
Macintyre, I. et al., "New Perspectives in Osteoporosis." 14:319-320 (1993).
Roudebush, Roger E. et al., "Effect of Weight Manipulation on Bone Loss Due to Ovariectomy and the Protective Effects of Estrogen in the Rat." CalcFied. Tissue Int. 53:61-64 (1993).
Williams, Janice A. et al., Dendrosapin: A Potent Integrin Receptor Inhibitor From the Venoms of Dendroapis viridis and D. jamesonii. Biochem. Soc. Transactions 21:73 (1992).
Gronowicz, Gloria A. and Derome, Mary E. "Synthetic Peptide Containing Arg-Gly-Asp Inhibits Bone Formation and Resorption in a Mineralizing Organ Culture System of Fetal Rat Parietal Bones." J. Bone and Mineral Res. 9:193-201 (1994).
Brooks, Peter C. et al., "Requirement of Vascular Integrin .alpha..sub.v .beta..sub.3 for Angiogenesis." Science 264:569-571 (1994).
Denis, Cecile et al., "Solid-Phase von Willebrand Factor Contains a Conformationally Active RGD Motif that Mediates Endothelial Cell Adhesion Through the .alpha..sub.v .beta..sub.3 Receptor." Blood 82:3622-3630 (1993).
Sato, Masahiko et al., "Structure-Activity Studies of the s-Echistatin Inhibition of Bone Resorption." J. Bone and Mineral Res. 9:1441-1449 (1994).
Young, Marian F. et al. "cDNA Cloning, mRNA Distribution and Heterogeneity, Chromosomal Location, and RFLP Analysis of Human Osteopontin (OPN)." Genomics 7:491-502 (1990). 8-.alpha.,.beta.-Diaminopropionic Acid! Vasopressin and Acid! Vasopressin. Two Lysine-Vasopressin Analogs With Considerable Antidiuretic Effect." Collection Czechoslov. Chem. Commun. 44:2161-2164 (1979).
Bauer, Wilfried et al., "SMS201-995: A Very Potent and Selective Octapeptide Analogue of Somatostatin with Prolonged Action." Life Science 31:1133-1140 (1982).
Aumailley et al., "Arg-Gly-Asp Constrained within Cyclic Pentapeptides Strong and Selective Inhibitors of Cell Adhesion to Vitronectin and Laminin Fragment P1," FEBS Letters 291 (1) :50-54 (1991).
Fauchere et al., "Modulation of the Activity and Assessment of the Receptor Selectivity in a Series of New RGD-containing Peptides," Int'l J. Peptide & Protein Res. 42(5):440-444 (1993).
PCT Search Report (dated 9 Nov. 1995), International application No. PCT/US95/04741.

Affiliated with

Also associated with

Rating

Peptides for reducing or inhibiting bone resorption does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptides for reducing or inhibiting bone resorption, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides for reducing or inhibiting bone resorption will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1394777